FDA Greenlights AbbVie’s Antibiotic Dalvance for Acute Skin Infections in Children

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jul 24, 2021 at 6:42 PM.

  1. #1 cafead, Jul 24, 2021 at 6:42 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,057
    Likes Received:
    3
    via The U.S. Food and Drug Administration (FDA) approved AbbVie’s Dalvance (dalbavancin) for acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients as young as newborns. The drug is given in a single-dose as a 30-mintue intravenous infusion. This approval is specifically for the treatment of ABSSSI caused by certain susceptible Gram-positive bacteria in children, including infections caused by methicillin-resistant Staphylococcus aureus (MRSA).

    article source
     
    Quote

Reply to Thread